Efficacy of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: An open-label, multicentre, randomised, controlled study

Journal of Family Planning and Reproductive Health Care

Volumn 38, Issue 2, 2012, Pages 94-101

  Strowitzki, Thomas ^a   Kirsch, Bodo ^b   Elliesen, Jörg ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ANDROSTANE DERIVATIVE; ORAL CONTRACEPTIVE AGENT;

ACNE; ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; PELVIS PAIN SYNDROME; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT OUTCOME; VAGINITIS; VOMITING; ADOLESCENT; CLINICAL TRIAL; DRUG ADMINISTRATION; PATIENT SATISFACTION; WOMEN'S HEALTH; YOUNG ADULT;

ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; DYSMENORRHEA; ETHINYL ESTRADIOL; FEMALE; HUMANS; PATIENT SATISFACTION; WOMEN'S HEALTH; YOUNG ADULT;

EID: 84860720055     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc-2011-100225     Document Type: Article

References (13)

1. Coco AS. Primary dysmenorrhea. Am Fam Physician 1999;60:489-496. (Pubitemid 29390269)
2. French L. Dysmenorrhea. Am Fam Physician 2005;71:285-291.
3. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006;108:428-441. (Pubitemid 44305687)
4. Davis AR, Westhoff CL. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J Pediatr Adolesc Gynecol 2001;14:3-8. (Pubitemid 32521106)
5. Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 1999;107:3S-8S; discussion 8S.
6. Wong CL, Farquhar C, Roberts H, et al. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009;4:CD002120.
7. Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005;3:CD004695.
8. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 1982;144:655-660. (Pubitemid 13233930)
9. Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997;89:179-183. (Pubitemid 27057203)
10. Machado RB, de Melo NR, Maia H Jr. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. Contraception 2010;81:215-222.
11. Seidman DS, Yeshaya A, Ber A, et al. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone. Isr Med Assoc J 2010;12:400-405.
12. Kwiecien M, Edelman A, Nichols MD, et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003;67:9-13. (Pubitemid 36084281)
13. Göretzlehner G, Waldmann-Rex S, Schramm GA. Extended cycles with the combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg: pooled analysis of data from three large-scale, non-interventional, observational studies. Clin Drug Investig 2011;31:269-277.